Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment
暂无分享,去创建一个
[1] S. Daniel. Chronic Hepatitis C Treatment Patterns in African American Patients: An Update , 2005, The American Journal of Gastroenterology.
[2] C. Nemeroff,et al. Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C , 2005, Brain, Behavior, and Immunity.
[3] P. Hauser,et al. Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care , 2004, Journal of Urban Health.
[4] B. Fischhoff,et al. Interactive video behavioral intervention to reduce adolescent females' STD risk: a randomized controlled trial. , 2004, Social science & medicine.
[5] T. Wise,et al. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. , 2004, Cleveland Clinic journal of medicine.
[6] Z. Younossi,et al. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. , 2004, Cleveland Clinic journal of medicine.
[7] S. Zickmund,et al. Hepatitis C virus‐infected patients report communication problems with physicians , 2004, Hepatology.
[8] M. Manns. Adherence to combination therapy: influence on sustained virologic response and economic impact. , 2004, Gastroenterology clinics of North America.
[9] J. McHutchison,et al. Future trends in managing hepatitis C. , 2004, Gastroenterology clinics of North America.
[10] C. Pariante,et al. Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-α: a Prospective Case Series and a Discussion of Biological Mechanisms , 2004 .
[11] H. Grunze,et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.
[12] William M. Lee,et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.
[13] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[14] R. Fontana,et al. Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C , 2002 .
[15] B. Johnson. Risk Communication: A Mental Models Approach , 2002 .
[16] C. Gonsalvez,et al. Fatigue and psychological disorders in chronic hepatitis C , 2002, Journal of gastroenterology and hepatology.
[17] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[18] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[19] J. Wong,et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.
[20] H. Bonkovsky,et al. Reduction of health‐related quality of life in chronic hepatitis C and improvement with interferon therapy , 1999, Hepatology.
[21] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[22] M. Bergner,et al. The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.
[23] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[24] Evelyn Y. Ho,et al. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. , 2003, Journal of general internal medicine.
[25] R. Fontana,et al. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. , 2002, Psychosomatics.
[26] oseph,et al. PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .
[27] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[28] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.